SLC5A2 and respiratory tract infectious disorder: Conversely, SGLT2 inhibitors were not associated with Fournier's gangrene [48], hospitalisation for Fournier's gangrene [27], respiratory infection or acute upper respiratory infection [42], confirmed or suspected COVID-19 [47], severe COVID-19 outcomes [32] and COVID-19-related pneumonia or sepsis [36].